22,000 employees

including 4,900 in France.

3 major R&D areas

oncology, neurology/immune-inflammatory and cardio-metabolism

100 million patients

treated daily with Servier medicinal products and generics.

150 countries

in which the Group’s medicines are distributed.

15 International Centres for Therapeutic Research

and 4 research institutes.

16 chemical & pharmaceutical production sites

4.7 billion euros in turnover

comprising 3.2 billion euros for Servier and 1.4 billion euros for generics.

23 % of turnover from Servier drugs is invested in R&D

excluding generics.

2nd largest pharmaceutical Group in France

31st largest pharmaceutical Group worldwide

A leader in cardiology

no. 6 Group in the world (Source: IQVIA Q3 2019).

27 projects

in clinical development, including 16 new molecular entities

Participation reached 36% of the trade balance surplus in France

In pharmaceuticals and fine chemicals (brand-name medicines), amounting to 1.6 billion euros.